Citations

Clear

3942 citation(s) found for "To, Van".

Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses
Johnson, Blair D. , Curry, Timothy B. , Buskirk, Camille M. van , Convertino, Víctor A. , Joyner, Michael J. , van Helmond, Noud, van Buskirk, Camille M, Helmond, Noud van , Johnson, Blair D , Joyner, Michael J

Mayo Clinic

Journal of Applied Physiology | May 30, 2014 | Volume: 117 | Issue: 2 | Pages: 131-141

10.1152/japplphysiol.00070.2014 | PMID 24876357 Get It

The purpose of this study was to compare hemodynamic and blood analyte responses to reduced central venous pressure (CVP) and pulse pressure (PP) elicited during graded lower body negative pressure (LBNP) to those observed during graded blood loss (BL) in conscious humans. We hypothesized that the stimulus-response relationships of CVP and PP to hemodynamic responses during LBNP would mimic those observed during BL. We assessed CVP, PP, heart rate, mean arterial pressure (MAP), and other hemodynamic markers in 12 men during LBNP and BL. Blood samples were obtained for analysis of catecholamines, hematocrit, hemoglobin, arginine vasopressin, and blood gases. LBNP consisted of 5-min stages at 0, 15, 30, and 45 mmHg of suction. BL consisted of 5 min at baseline and following three stages of 333 ml of hemorrhage (1,000 ml total). Individual r2 values and linear regression slopes were calculated to determine whether the stimulus (CVP and PP)-hemodynamic response trajectories were similar between protocols. The CVP-MAP trajectory was the only CVP-response slope that was statistically different during LBNP compared with BL (0.93 ± 0.27 vs. 0.13 ± 0.26; P = 0.037). The PP-heart rate trajectory was the only PP-response slope that was statistically different during LBNP compared with BL (−1.85 ± 0.45 vs. −0.46 ± 0.27; P = 0.024). Norepinephrine, hematocrit, and hemoglobin were all lower at termination in the BL protocol compared with LBNP ( P < 0.05). Consistent with our hypothesis, LBNP mimics the hemodynamic stimulus-response trajectories observed during BL across a significant range of CVP in humans.
An investigation into false‐negative transthoracic fine needle aspiration and core biopsy specimens
Minot, Douglas M., Gilman, Elizabeth A. , Aubry, Marie‐Christine, Voss, Jesse S. , Epps, Sarah G. Van, Tuve, Delores J, Sciallis, Andrew P. , Henry, Michael , Salomão, Diva R. , Carlson, Stephanie K., Clayton, Amy C., Aubry, Marie-Christine, Lee, Peter

Mayo Clinic

Diagnostic Cytopathology | May 28, 2014 | Volume: 42 | Issue: 12 | Pages: 1063-1068

10.1002/dc.23169 | PMID 24866385 Get It

Transthoracic fine needle aspiration (TFNA)/core needle biopsy (CNB) under computed tomography (CT) guidance has proved useful in the assessment of pulmonary nodules. We sought to determine the TFNA false‐negative (FN) rate at our institution and identify potential causes of FN diagnoses. Medical records were reviewed from 1,043 consecutive patients who underwent CT‐guided TFNA with or without CNB of lung nodules over a 5‐year time period (2003–2007). Thirty‐seven FN cases of “negative” TFNA/CNB with malignant outcome were identified with 36 cases available for review, of which 35 had a corresponding CNB. Cases were reviewed independently (blinded to original diagnosis) by three pathologists with 15 age‐ and sex‐matched positive and negative controls. Diagnosis (i.e., nondiagnostic, negative or positive for malignancy, atypical or suspicious) and qualitative assessments were recorded. Consensus diagnosis was suspicious or positive in 10 (28%) of 36 TFNA cases and suspicious in 1 (3%) of 35 CNB cases, indicating potential interpretive errors. Of the 11 interpretive errors (including both suspicious and positive cases), 8 were adenocarcinomas, 1 squamous cell carcinoma, 1 metastatic renal cell carcinoma, and 1 lymphoma. The remaining 25 FN cases (69.4%) were considered sampling errors and consisted of 7 adenocarcinomas, 3 nonsmall cell carcinomas, 3 lymphomas, 2 squamous cell carcinomas, and 2 renal cell carcinomas. Interpretive and sampling error cases were more likely to abut the pleura, while histopathologically, they tended to be necrotic and air‐dried. The overall FN rate in this patient cohort is 3.5% (1.1% interpretive and 2.4% sampling errors). Diagn. Cytopathol. 2014;42:1063–1068;. © 2014 Wiley Periodicals, Inc.
Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis
Valent, Peter , Escribano, Luís, Broesby‐Olsen, Sigurd , Hartmann, Karin , Grattan, Clive , Niedoszytko, Marek , Nedoszytko, Bogusław , Elberink, J. N. G. Oude, Kristensen, Thomas Kielsgaard , Butterfield, Joseph H. , Triggiani, Massimo , Álvarez‐Twöse, Iván , Reiter, Andreas , Sperr, Wolfgang R. , Sotlar, Karl , Yavuz, Selim , Kluin‐Nelemans, Hanneke C. , Hermine, Olivier , Radia, Deepti , Doormaal, J. J. van, Orfao, A., Siebenhaar, Frank , Schwartz, Lawrence B. , Maurer, Marcus , Horny, H.‐P., Akin, Cem , Metcalfe, Dean D. , Arock, Michel , Brockow, Knut , Gotlib, Jason , Orfao, A., Castells, Mariana , Sperr, Wolfgang , Valent, Peter , Hermine, Olivier , Akin, Cem , Arock, Michel , Kluin-Nelemans, Hanneke C

Mayo Clinic

Allergy | May 19, 2014 | Volume: 69 | Issue: 10 | Pages: 1267-1274

10.1111/all.12436 | PMID 24836395 Get It

AbstractMastocytosis is an emerging differential diagnosis in patients with more or less specific mediator‐related symptoms. In some of these patients, typical skin lesions are found and the diagnosis of mastocytosis can be established. In other cases, however, skin lesions are absent, which represents a diagnostic challenge. In the light of this unmet need, we developed a diagnostic algorithm for patients with suspected mastocytosis. In adult patients with typical lesions of mastocytosis in the skin, a bone marrow (BM) biopsy should be considered, regardless of the basal serum tryptase concentration. In adults without skin lesions who suffer from mediator‐related or other typical symptoms, the basal tryptase level is an important parameter. In those with a slightly increased tryptase level, additional investigations, including a sensitive KIT mutation analysis of blood leucocytes or measurement of urinary histamine metabolites, may be helpful. In adult patients in whom (i) KIT D816V is detected and/or (ii) the basal serum tryptase level is clearly increased (>25–30 ng/ml) and/or (iii) other clinical or laboratory features suggest the presence of ‘occult’ mastocytosis or another haematologic neoplasm, a BM investigation is recommended. In the absence of KIT D816V and other signs or symptoms of mastocytosis or another haematopoietic disease, no BM investigation is required, but the clinical course and tryptase levels are monitored in the follow‐up. In paediatric patients, a BM investigation is usually not required, even if the tryptase level is increased. Although validation is required, it can be expected that the algorithm proposed herein will facilitate the management of patients with suspected mastocytosis and help avoid unnecessary referrals and investigations.
The past, present, and future of telemedicine for Parkinson's disease
Achey, Meredith A. , Aldred, Jason , Aljehani, Noha, Bloem, Bastiaan R. , Biglan, Kevin , Chan, Piu, Cubo, Esther , Dorsey, E. Ray , Guttman, Mark, Hassan, Anhar , Khandhar, Suketu M., Spindler, Meredith , Haak, Pieter van den , Walker, Richard , Wilkinson, Jayne , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task, Goetz, Christopher G. , Mari, Zoltan K. , Tanner, Caroline M. , Force, on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task

Mayo Clinic

Movement Disorders | May 17, 2014 | Volume: 29 | Issue: 7 | Pages: 871-883

10.1002/mds.25903 | PMID 24838316 Get It

ABSTRACT Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more‐extensive, less‐expensive participation in research. © 2014 International Parkinson and Movement Disorder Society
Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care
Blay, Jean‐Yves , Sobrero, Alberto , George, Suzanne , van Cutsem, Eric, Demetri, George D., Grothey, Axel , Cutsem, Eric Van , Demetri, George D. , Blay, Jean-Yves

Mayo Clinic

The Oncologist | May 13, 2014 | Volume: 19 | Issue: 6 | Pages: 669-680

10.1634/theoncologist.2013-0059 | PMID 24821824 Get It

Abstract Regorafenib is an oral multikinase inhibitor that inhibits several kinases relevant to tumor biology in several cancers, including colorectal carcinoma (CRC) and gastrointestinal stromal tumor (GIST). In phase III trials, regorafenib significantly improved overall survival versus placebo in patients with metastatic CRC progressing after all available standard therapies, and significantly prolonged progression-free survival in patients with advanced GIST in whom at least imatinib and sunitinib had failed. Thus, this agent holds promise as a new standard of care for CRC and GIST patients after disease progression following all other approved therapies. The clinical trials reported to date show that this new treatment has a consistent adverse event profile that is quite different from that of traditional cytotoxic chemotherapies. The most common adverse events of regorafenib include dermatologic and mucosal toxicities (especially hand-foot skin reaction, rash, and oral mucositis), constitutional symptoms (e.g., fatigue, nausea, and weight loss), vascular effects (especially hypertension), and gastrointestinal symptoms (e.g., diarrhea). To help health care professionals anticipate and manage the adverse events associated with regorafenib, we describe our experiences in clinical trials and show that such toxicities can be effectively managed with close observation of patients from initiation of dosing, along with prompt appropriate interventions, including dose modifications, if necessary.
Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability
Daams, Marita , Weiler, Florian , Steenwijk, Martijn D. , Hahn, Horst K. , Geurts, Jeroen J.G. , Schijndel, Ronald A. van , Balk, Lisanne J. , Tewarie, Prejaas , Tillema, Jan‐Mendelt , Killestein, Joep , Uitdehaag, Bernard M.J. , Barkhof, Frederik , Vrenken, Hugo , Barkhof, Frederik

Mayo Clinic

Multiple Sclerosis Journal | May 9, 2014 | Volume: 20 | Issue: 14 | Pages: 1860-1865

10.1177/1352458514533399 | PMID 24812042 Get It

Background: The majority of patients with multiple sclerosis (MS) present with spinal cord pathology. Spinal cord atrophy is thought to be a marker of disease severity, but in long-disease duration its relation to brain pathology and clinical disability is largely unknown. Objective: Our aim was to investigate mean upper cervical cord area (MUCCA) in patients with long-standing MS and assess its relation to brain magnetic resonance imaging (MRI) measures and clinical disability. Methods: MUCCA was measured in 196 MS patients and 55 healthy controls using 3DT1-weighted cervical images obtained at 3T MRI. Clinical disability was measured using the Expanded Disability Status Scale (EDSS), Nine-Hole-Peg test (9-HPT), and 25 feet Timed Walk Test (TWT). Stepwise linear regression was performed to assess the association between MUCCA and MRI measures, and between MUCCA and clinical disability. Results: MUCCA was smaller (mean 11.7%) in MS patients compared with healthy controls (72.56±9.82 and 82.24±7.80 mm 2 respectively; p<0.001), most prominently in male patients. MUCCA was associated with normalized brain volume, and number of cervical cord lesions. MUCCA was independently associated with EDSS, TWT, and 9-HPT. Conclusion: MUCCA was reduced in MS patients compared with healthy controls. It provides a relevant marker for clinical disability in long-standing disease, independent of other MRI measures.
RUNX3 Facilitates Growth of Ewing Sarcoma Cells
Bledsoe, Krista L., McGee‐Lawrence, Meghan E. , Camilleri, Emily T. , Riester, Scott M. , Wijnen, André J. van , Oliveira, André M. , Camilleri, Emily , Wang, Xiaoke , Westendorf, Jennifer J. , van Wijnen, Andre J , McGee-Lawrence, Meghan E , Camilleri, Emily

Mayo Clinic

Journal of Cellular Physiology | May 8, 2014 | Volume: 229 | Issue: 12 | Pages: 2049-2056

10.1002/jcp.24663 | PMID 24812032 Get It

Ewing sarcoma is an aggressive pediatric small round cell tumor that predominantly occurs in bone. Approximately 85% of Ewing sarcomas harbor the EWS/FLI fusion protein, which arises from a chromosomal translocation, t(11:22)(q24:q12). EWS/FLI interacts with numerous lineage‐essential transcription factors to maintain mesenchymal progenitors in an undifferentiated state. We previously showed that EWS/FLI binds the osteogenic transcription factor RUNX2 and prevents osteoblast differentiation. In this study, we investigated the role of another Runt‐domain protein, RUNX3, in Ewing sarcoma. RUNX3 participates in mesenchymal‐derived bone formation and is a context dependent tumor suppressor and oncogene. RUNX3 was detected in all Ewing sarcoma cells examined, whereas RUNX2 was detected in only 73% of specimens. Like RUNX2, RUNX3 binds to EWS/FLI via its Runt domain. EWS/FLI prevented RUNX3 from activating the transcription of a RUNX‐responsive reporter, p6OSE2. Stable suppression of RUNX3 expression in the Ewing sarcoma cell line A673 delayed colony growth in anchorage independent soft agar assays and reversed expression of EWS/FLI‐responsive genes. These results demonstrate an important role for RUNX3 in Ewing sarcoma. J. Cell. Physiol. 229: 2049–2056, 2014. © 2014 Wiley Periodicals, Inc.
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
Jessen, Frank , Amariglio, Rebecca E. , Breteler, Monique M.B. , Ceccaldi, Mathieu , Chételat, Gaël , Dubois, Bruno , Dufouil, Carole , Ellis, Kathryn A. , Flier, Wiesje M. van der , Glodzik, Lidia , Harten, Argonde C. van , Leon, Mony J. de , McHugh, Pauline, Mielke, Michelle M. , Molinuevo, José Luís , Mosconi, Lisa , Osorio, Ricardo S. , Perrotin, Audrey , Petersen, Ronald C. , Rabin, Laura A., Rami, Lorena , Reisberg, ‌Barry , Sachdev, Perminder S. , Sayette, Vincent de La , Saykin, Andrew J. , Scheltens, Philip , Shulman, Melanie , Slavin, Melissa J., Stewart, Robert , Uspenskaya, Olga, Vellas, Bruno , Visser, Pieter Jelle , Wagner, Michael , Group, Subjective Cognitive Decline Initiative (SCD‐I) Working, Boxtel, Martin P.J. van , Rentz, Dorene M. , Sperling, Reisa Anne , Stewart, Robert , Group, Subjective Cognitive Decline Initiative (SCD‐I) Working, Mielke, Michelle M , Saykin, Andrew J , Sachdev, Perminder S , van der Flier, Wiesje M , Scheltens, Philip , Molinuevo, José Luis

Mayo Clinic

Alzheimer's & Dementia | May 3, 2014 | Volume: 10 | Issue: 6 | Pages: 844-852

10.1016/j.jalz.2014.01.001 | PMID 24798886 Get It

Abstract There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD‐I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre‐mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus .
Interictal Scalp Electroencephalography and Intraoperative Electrocorticography in Magnetic Resonance Imaging–Negative Temporal Lobe Epilepsy Surgery
Burkholder, David B. , Šulc, Vlastimil , Hoffman, E. Matthew , Cascino, Gregory D. , So, Elson L., Marsh, W. Richard , Meyer, Fredric B. , Wass, C. Thomas, Watson, Robert E. , Van Gompel, Jamie J, Britton, Jeffrey W. , Gompel, Jamie J. Van , Giannini, Caterina , Worrell, Gregory A. , Burkholder, David B

Mayo Clinic

JAMA Neurology | April 28, 2014 | Volume: 71 | Issue: 6 | Pages: 702

10.1001/jamaneurol.2014.585 | PMID 24781216 Get It

Mucormycosis in Patients with Inflammatory Bowel Disease: Case Series and Review of the Literature
Abidi, Maheen Z. , Weiland, Tim, Dyken, Irminne Van, Tande, Aaron J. , Tosh, Pritish K. , Walker, Randall C., Coelho-Prabhu, Nayantara , Tande, Aaron , Cummins, Nathan W. , Coelho–Prabhu, Nayantara , Hargreaves, James , Abidi, Maheen Z , Abidi, Maheen Z

Mayo Clinic

Case Reports in Medicine | April 27, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-7

10.1155/2014/637492 | PMID 24872818 Get It

Mucormycosis is a rare and often fatal invasive fungal infection mostly seen in immune-compromised individuals. A high index of clinical suspicion is necessary, so that effective preemptive therapy can be started, as timely intervention is crucial. In this series we present three cases of invasive mucormycosis in patients with underlying inflammatory bowel disease that had received therapy with immunomodulators prior to the infection. All three had varied clinical manifestations. We also review the literature of invasive mucormycosis in patients with inflammatory bowel disease.